This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by VON KAULLA, K. N. Search for Related Content PubMed PubMed Citation Articles by VON KAULLA, K. N.

(Circulation. 1958;17:187.)
© 1958 American Heart Association, Inc.

---

Intravenous Protein-Free Pyrogen

A Powerful Fibrinolytic Agent in Man

KURT N. VON KAULLA M.D.¹

¹ From the Department of Medicine, University of Colorado School of Medicine and the Belle Bonfils Memorial Blood Bank, Denver, Colo.

Administration of a variety of nonfibrinolytic, nonenzymatic substances induces fibrinolysis in man. The most potent materials of this type known at present are purified protein-free pyrogens. Their action after intravenous injection on the human fibrinolytic system, on some of its components, and on the clotting system of 67 individuals has been studied. The possible therapeutic implications are discussed of the marked fibrinolysis.

This article has been cited by other articles:

				E. E. Cliffton The Present Status of Fibrinolytic Therapy Angiology, November 1, 1963; 14(11): 533 - 541. [PDF]

				E. E. Cliffton and R. L. Clarke Induction of Fibrinolysis By Hyperventilation With Oxygen and Carbon Dioxide Angiology, June 1, 1963; 14(6): 285 - 287. [PDF]

				Y. I. Misirlioglu and C. W. Lillehei The Physiologic Enzymes Activating Profibrinolysin To Fibrinolysin, and the Substances Which Inhibit Activation: Localizations, Clinical Importance and Pathogenesis Angiology, May 1, 1962; 13(5): 185 - 207. [PDF]

				R. J. Popkin Medical Treatment of Peripheral Vascular Diseases Angiology, September 1, 1961; 12(9): 427 - 431. [PDF]

				N. C. Whissen, K. M. Moser, and G. C. Hajjar Diurnal Variation in Plasma Euglobulin Activity and Fibrinogen Levels*{dagger}: Preliminary Report Angiology, May 1, 1961; 12(5): 160 - 164. [PDF]

				H. M. Starling and W. A. Randolph Fibrinolysin Therapy in Thromboembolic Diseasea Angiology, May 1, 1961; 12(5): 179 - 194. [PDF]

				K. M. Moser Intravenous Administration of Fibrinolysin: Its Systemic Toxicity and Effect Upon Components of the Coagulation Mechanism Angiology, August 1, 1959; 10(4): 253 - 258. [PDF]